Results 241 to 250 of about 10,864 (278)
Some of the next articles are maybe not open access.
Effect of Brimonidine on Corneal Thickness
Journal of Ocular Pharmacology and Therapeutics, 2011Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication that is widely used in glaucoma treatment. Although it is known that it is quickly taken up by the cornea following topical administration and that the cornea has alpha-2 adrenoceptors, there are only few studies available on the impact brimonidine has on the cornea ...
Torsten Schlote +3 more
openaire +3 more sources
Expert Review of Clinical Pharmacology, 2022
Introduction Ocular redness, or conjunctival hyperemia, is a common ophthalmic sign associated with reduced quality of life. For redness without apparent underlying pathology, topical ophthalmic decongestants have been widely used.
J. Lee, Chan-Yun Kim
semanticscholar +1 more source
Introduction Ocular redness, or conjunctival hyperemia, is a common ophthalmic sign associated with reduced quality of life. For redness without apparent underlying pathology, topical ophthalmic decongestants have been widely used.
J. Lee, Chan-Yun Kim
semanticscholar +1 more source
A paradoxical ocular effect of brimonidine
American Journal of Ophthalmology, 2003We report an unusual paradoxical effect of brimonidine.Observational case report.A 70-year-old woman with bilateral normal tension glaucoma was treated with topical brimonidine and followed in an outpatient setting. The main outcome measured was intraocular pressure (IOP) in mm Hg.Brimonidine was observed to cause IOP elevation, confirmed on ...
Tim D. Matthews +2 more
openaire +3 more sources
Journal of glaucoma, 2022
Précis: We investigate the efficacy of triple-fixed-combination of bimatoprost/brimonidine/timolol once and twice a day, demonstrating higher intraocular pressure reduction with once-a-day use, and discuss possible implications based on previous ...
B. Susanna +6 more
semanticscholar +1 more source
Précis: We investigate the efficacy of triple-fixed-combination of bimatoprost/brimonidine/timolol once and twice a day, demonstrating higher intraocular pressure reduction with once-a-day use, and discuss possible implications based on previous ...
B. Susanna +6 more
semanticscholar +1 more source
Efficacy, safety, and current applications of brimonidine
Expert Opinion on Drug Safety, 2008The use of brimonidine to lower intraocular pressure has been the subject of considerable investigation. Variations of the initially approved drug including agents of a lower concentration (Alphagan P 0.15 and 0.1%, Allergan, Inc., Irvine, CA, USA) and a fixed-combination mating brimonidine with timolol (Combigan, Allergan) evolved the marketing and ...
L. Jay Katz +2 more
openaire +3 more sources
Ocular immunology and inflammation, 2022
Introduction Brimonidine is a commonly used drug for glaucoma treatment, which has been linked to ocular autoimmune disorders like uveitis and conjunctivitis. Corneal pathology under brimonidine is generally less common.
L. Vidal Oliver +4 more
semanticscholar +1 more source
Introduction Brimonidine is a commonly used drug for glaucoma treatment, which has been linked to ocular autoimmune disorders like uveitis and conjunctivitis. Corneal pathology under brimonidine is generally less common.
L. Vidal Oliver +4 more
semanticscholar +1 more source
Improved Treatment Options for Glaucoma with Brimonidine-Loaded Lipid DNA Nanoparticles.
ACS Applied Materials and Interfaces, 2021Glaucoma is the second leading cause of irreversible blindness worldwide. Among others, elevated intraocular pressure (IOP) is one of the hallmarks of the disease. Antiglaucoma drugs such as brimonidine can lower the IOP but their adherence to the ocular
S. Schnichels +9 more
semanticscholar +1 more source
Drug Development and Industrial Pharmacy, 2021
Objective The present study was aimed to design and optimize brimonidine tartrate (BRT) loaded cationic-charged liposome formulation with enhanced trans-corneal drug permeation, prolonged corneal residence, and sustained drug release for effective ocular
P. K. Soni, T. Saini
semanticscholar +1 more source
Objective The present study was aimed to design and optimize brimonidine tartrate (BRT) loaded cationic-charged liposome formulation with enhanced trans-corneal drug permeation, prolonged corneal residence, and sustained drug release for effective ocular
P. K. Soni, T. Saini
semanticscholar +1 more source
Biotechnology and applied biochemistry, 2021
Oxidative stress is to upregulate the pentose phosphate pathway (PPP). The PPP consists of two functional branches, glucose‐6‐phosphate dehydrogenase (G6PD) and 6‐phosphogluconaste dehydrogenase (6PGD).
Büşra Çalışkan +3 more
semanticscholar +1 more source
Oxidative stress is to upregulate the pentose phosphate pathway (PPP). The PPP consists of two functional branches, glucose‐6‐phosphate dehydrogenase (G6PD) and 6‐phosphogluconaste dehydrogenase (6PGD).
Büşra Çalışkan +3 more
semanticscholar +1 more source
Evidence on the neuroprotective properties of brimonidine in glaucoma
2020glaucoma is the leading cause of irreversible blindness all over the world. The degree of visual field loss accounts for the severity of the disease and represents the main clinical outcome of treatment for patients affected by glaucoma. The α2 agonists, like brimonidine, emerged in the 1960s as topical ophthalmologic treatment.
Scuteri D. +6 more
openaire +5 more sources